2021
DOI: 10.1016/j.bios.2021.113356
|View full text |Cite
|
Sign up to set email alerts
|

Label-free E-DNA biosensor based on PANi-RGO-G*NPs for detection of cell-free fetal DNA in maternal blood and fetal gender determination in early pregnancy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…Table 3 provides the efficiency of our proposed method, including LOD, linear range, and response time of other biosensing approaches for the determination of cffDNA in maternal plasma. As is evident from the table, our single and dual nanobiosensors showed appropriate LODs, linear ranges, and response time compared to other single biosensors previously reported [ 16 , 17 , 37 , 38 ]. Our simple fluorescence approach for SRY and DYS14 detection exhibits an acceptable linear range and a LOD comparable to other fluorescent approaches [ 35 , 36 ].…”
Section: Resultssupporting
confidence: 60%
See 2 more Smart Citations
“…Table 3 provides the efficiency of our proposed method, including LOD, linear range, and response time of other biosensing approaches for the determination of cffDNA in maternal plasma. As is evident from the table, our single and dual nanobiosensors showed appropriate LODs, linear ranges, and response time compared to other single biosensors previously reported [ 16 , 17 , 37 , 38 ]. Our simple fluorescence approach for SRY and DYS14 detection exhibits an acceptable linear range and a LOD comparable to other fluorescent approaches [ 35 , 36 ].…”
Section: Resultssupporting
confidence: 60%
“…Therefore, the results indicated that proposed DNA biosensor could be used for SRY gene and DYS14 marker detection in plasma matrices. Most of the studies conducted so far have detected the SRY gene alone or the DYS14 marker using free fetal DNA [ 16 , 17 , 37 ]. In this work, both of these markers were detected simultaneously in the optimal time of 28 min with this sensing platform.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Fetal DNA is released into maternal blood, allowing Y chromosome detection in pregnancies with a male fetus. cfDNA can also be used for non-invasive prenatal Down syndrome screening ( Vrachnis et al, 2014 ; Malmir et al, 2021 ) and immune rejection surveillance after organ transplantation ( Snyder et al, 2016 ; Danovitch et al, 2021 ). The third source is the release of auto-activated DNA, cfDNA content is related to trauma, burn, infection, heart failure, stroke, and organ IRI level ( Tian et al, 2019 ; Dinsdale et al, 2020 ; Yokokawa et al, 2020 ; Zuo et al, 2020 ; Saravanan et al, 2021 ).…”
Section: Cfdna Sources Distribution Content and Detection Methodsmentioning
confidence: 99%
“…However, a previous report shown that MoS 2 nanosheets present poor electrochemical sensing properties and agglomeration due to its inherent semiconductor properties ( Wang et al, 2018 ). As a typical two-dimensional material, reduced graphene oxide (rGO) and reduced graphene-based composites had been widely used as substrate material for aptasensor due to their large specific surface area, good electrical conductivity and anti-agglomeration behavior ( Lyu et al, 2021 ), such as DNA ( Malmir et al, 2021 ), protein ( Sonuc Karaboga and Sezginturk, 2020 ) and biomarker ( Kasturi et al, 2021 ) detections. Therefore, the composite material coupling MoS 2 with rGO can be an excellent substrate material for electrochemical sensing ( Han et al, 2021 ).…”
Section: Introductionmentioning
confidence: 99%